NanoViricides Signs Master Services Agreement with Only Orphans Cote for Orphan Drug Strategy
I'm PortAI, I can summarize articles.
NanoViricides Inc. has signed a Master Services Agreement with Only Orphans Cote, LLC to develop an orphan drug strategy for its antiviral candidate NV-387. The agreement involves preparing and prosecuting orphan drug designation applications with the US FDA. This collaboration aims to advance NV-387's regulatory pathway as an orphan drug.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments